United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - atovaquone; proguanil hydrochloride - oral tablet - 250mg ; 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - atovaquone; proguanil hydrochloride - oral tablet - 250mg ; 100mg

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - proguanil hydrochloride; atovaquone - film-coated tablet - 250/100 milligram(s) - biguanides; proguanil, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

primecrown 2010 ltd - atovaquone, proguanil hydrochloride - film coated tablet - 250/100 milligram - biguanides

United States - English - NLM (National Library of Medicine)

a-s medication solutions - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt), proguanil hydrochloride (unii: r71y86m0wt) (proguanil - unii:s61k3p7b2v) - atovaquone 250 mg - malarone is indicated for the prophylaxis of plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. malarone is indicated for the treatment of acute, uncomplicated p. falciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance. risk summary available data from published literature and postmarketing experience with use of malarone in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. the proguanil component of malarone acts to inhibit parasitic dihydrofolate reductase; however, pregnant women and females of reproductive potential should continue folate supplementation to prevent neural tube defects [see clinical pharmacology (12.1)] . pregnant women with malaria are at increased risk for adverse pregnancy outcomes (see clin

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - atovaquone 250mg; proguanil hydrochloride 100mg - film coated tablet - active: atovaquone 250mg proguanil hydrochloride 100mg excipient: colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry brown 03c86943 poloxamer sodium starch glycolate tolpovidone i 131 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for: · prophylaxis of plasmodium falciparum malaria in adults · treatment of plasmodium falciparum malaria in adults.

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - film-coated tablet - atovaquone 250 mg proguanil hydrochloride 100 mg - antiprotozoals

Canada - English - Health Canada

glaxosmithkline inc - atovaquone; proguanil hydrochloride - tablet - 250mg; 100mg - atovaquone 250mg; proguanil hydrochloride 100mg - antimalarials

Canada - English - Health Canada

glaxosmithkline inc - atovaquone; proguanil hydrochloride - tablet - 62.5mg; 25.0mg - atovaquone 62.5mg; proguanil hydrochloride 25.0mg - miscellaneous antiprotozoals

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt) - atovaquone 750 mg in 5 ml - atovaquone oral suspension is indicated for the prevention of pneumocystis jirovecii pneumonia (pcp) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (tmp-smx).  atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderate pcp in adults and adolescents (aged 13 years and older) who cannot tolerate tmp-smx.  clinical experience with atovaquone oral suspension for the treatment of pcp has been limited to subjects with mild-to-moderate pcp (alveolar-arterial oxygen diffusion gradient [(a-a)do2 ] ≤45 mm hg). treatment of more severe episodes of pcp with atovaquone oral suspension has not been studied. the efficacy of atovaquone in subjects who are failing therapy with tmp-smx has also not been studied.  atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension. risk summary available data from postmarketing experience with use of atovaquone in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. pregnant women with hiv who are infected with pcp are at increased risk of adverse pregnancy outcomes (see clinical considerations) . atovaquone given orally by gavage to pregnant rats and rabbits during organogenesis did not cause fetal malformations at plasma concentrations up to 3 times and 0.5 times, respectively, the estimated human exposure based on steady-state plasma concentrations (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk: pregnant women with hiv who are infected with pcp are at increased risk of severe illness and maternal death associated with pcp compared with non-pregnant women. data animal data: atovaquone administered in oral doses of 250 mg/kg/day, 500 mg/kg/day, and 1,000 mg/kg/day to pregnant rats during organogenesis (gestation day [gd] 6 to gd15) did not cause maternal or embryo-fetal toxicity at doses up to 1,000 mg/kg/day corresponding to maternal plasma concentrations approximately 3 times the estimated human exposure during the treatment of pcp based on steady-state plasma concentrations. in pregnant rabbits, atovaquone administered in oral doses of 300 mg/kg/day, 600 mg/kg/day, and 1,200 mg/kg/day during organogenesis (gd6 to gd18) caused decreased fetal body length at a maternally toxic dose of 1,200 mg/kg/day corresponding to a plasma concentration that is approximately 0.5 times the estimated human exposure based on steady-state plasma concentrations. in a pre- and post-natal study in rats, atovaquone administered in oral doses of 250, 500, and 1,000 mg/kg/day from gd15 until lactation day (ld) 20 did not impair the growth or developmental effects in first generation offspring at doses up to 1,000 mg/kg/day corresponding to approximately 3 times the estimated human exposure based on steady-state plasma concentrations during the treatment of pcp. atovaquone crossed the placenta and was present in fetal rat and rabbit tissue. risk summary the centers for disease control and prevention recommend that hiv-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of hiv-1. there are no data on the presence of atovaquone in human milk, the effects on the breastfed child, or the effects on milk production. atovaquone was detected in rat milk when lactating rats were administered oral atovaquone (see data) . when a drug is present in animal milk, it is likely the drug will be present in human milk. because of the potential for hiv-1 transmission to hiv-negative infants, instruct mothers with hiv-1 not to breastfeed if they are taking atovaquone for the prevention or treatment of pcp. data in a rat study with doses of 10 mg/kg and 250 mg/kg given orally by gavage on postpartum day 11, atovaquone concentrations in the milk were 30% of the concurrent atovaquone concentrations in the maternal plasma at both doses. the concentration of drug in animal milk does not necessarily predict the concentration of drug in human milk. evidence of safety and effectiveness in pediatric patients (aged 12 years and younger) has not been established. in a trial of atovaquone oral suspension administered once daily with food for 12 days to 27 hiv-1-infected, asymptomatic infants and children aged between 1 month and 13 years, the pharmacokinetics of atovaquone were age-dependent. the average steady-state plasma atovaquone concentrations in the 24 subjects with available concentration data are shown in table 5. table 5. average steady-state plasma atovaquone concentrations in pediatric subjects age dose of atovaquone oral suspension 10 mg/kg 30 mg/kg 45 mg/kg average css in mcg/ml (mean ± sd) 1 to 3 months 5.9 (n = 1) 27.8 ± 5.8 (n = 4) _ >3 to 24 months 5.7 ± 5.1 (n = 4) 9.8 ± 3.2 (n = 4) 15.4 ± 6.6 (n = 4) >2 to 13 years 16.8 ± 6.4 (n = 4) 37.1 ± 10.9 (n = 3) _ css = concentration at steady-state. clinical trials of atovaquone did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects.